Stemline Therapeutics (STML) Tops Q3 EPS by 5c

Stemline Therapeutics (NASDAQ: STML) reported Q3 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $71.4 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping withdraws bid to acquire Genco Shipping
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c